(Source: Bellicum Pharmaceuticals Inc) Bellicum Announces Data Presentations on Lead Product Candidate BPX-501 and CAR-T and TCR Pipeline Programs at the 57th American Society of Hematology (ASH) Annual Meeting Seven abstracts accepted including oral presentation on the Company’s controllable CAR-T product candidate BPX-401 HOUSTON--(BUSINESS WIRE)--Nov. 5, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that three abstracts on the Company’s lead product candidate, BPX-501, an adjunct T cell therapy for...
↧